Shares of Assertio Therapeutics ASRT rose 9% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).
Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 11, 2020
Time: 08:01 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/vryis85c
Technicals
52-week high: $4.92
Company's 52-week low was at $0.55
Price action over last quarter: Up 10.80%
Company Description
Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.